SHOW / EPISODE

GLP-1s As A Treatment for Alzheimer's Disease - James Breaks Down the Science

8m | Oct 9, 2026

In this episode of the Gillett Health Podcast, James O'Hara, NP , breaks down the latest evidence surrounding

GLP-1 receptor agonists (like semaglutide) and their potential role in Alzheimer's disease and long-term

cognitive health.

While recent clinical trial results show that oral semaglutide does not reverse established Alzheimer's dementia,

could GLP-1s still play a powerful role in preventing cognitive decline?

Key Topics Covered:

Top-line trial results for oral semaglutide in Alzheimer's disease

Observational data showing lower cognitive risk in diabetics on GLP-1s

Changes in the blood biomarker p-tau217

How reducing cravings for sugar, alcohol, and nicotine protects cognitive reserve

Timestamps:

0:00 - Welcome & Introduction

0:38 - GLP-1s and Failed Alzheimer's Reversal Trials

1:22 - Observational Data & PTOW-217 Biomarker

2:21 - Can GLP-1s Be Used for Alzheimer's Prevention?

3:33 - Lifestyle, Cravings, & Risk Factor Reduction

4:48 - Diet Quality Impact & Final Thoughts



Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy
Paused
Audio Player Image
The Gillett Health Podcast
Loading...